Evaluation of Consumption of Sevoflurane in Chronic Obstructive Pulmonary Disease Patients

Evaluation of Consumption of Sevoflurane in Chronic Obstructive Pulmonary Disease Patients Under General Anesthesia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06108973

Acronym

SevoCOPD

Enrollment

Registered

2023-10-31

Start date

2024-01-01

Completion date

2025-03-30

Last updated

2023-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Brief summary

All the Patients undergoing General Anesthesia and the patients who are having Chronic Obstructive Pulmonary Disease will be considered for this study. The Volume consumption of Sevoflurane will be studied in accordance with age, sex, duration , type of surgery, site of surgery and BMI.The volume consumption of sevoflurane is compared with Chronic Obstructive Pulmonary Disease and Normal Patients .

Detailed description

Chronic Obstructive pulmonary disease is known to escalate the consumption of Inhalation Agents in General Anesthesia. Hence the Data to Collect the Official Record

Interventions

DEVICECapnography

To know the Co2 graph in COPD and Normal patients under General Anesthesia

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Both Sex All Age Group Patient willing to give consent COPD patient

Exclusion criteria

* Not willing to give consent Cancerous Lung Lung Lobectomy

Design outcomes

Primary

Measure	Time frame	Description
Estimation of Volume consumption of Sevoflurane	8 weeks	The consumption is expressed in Volume ml/kg

Contacts

Primary ContactSanthosh Kumar T N, BSc

tumakuru572102@gmail.com6366470104

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026